Health Care·Life Sciences Tools & Services·$6.6B
| Metric | Actual | Expected | Surprise |
|---|---|---|---|
| EPS | $0.08 | N/A | +0.00% |
| Revenue | N/A | N/A | N/A |
management commentary, guidance changes, and full analysis available with Pro.
| EPS | $0.08 | N/A | +0.00% |
| Revenue | N/A | N/A | N/A |
Tone: Defensive
Management's commentary reflected caution regarding market conditions. They did not offer any forward-looking guidance, indicating uncertainty.
Management did not provide specific guidance for future quarters.
The company acknowledged challenges in the current market environment.
Repligen Corp's earnings report showed a small EPS of $0.08, but without revenue figures or guidance, investors may feel uncertain about the company's future. The stock dropped 5.67% in reaction, likely due to the lack of clarity and management's cautious tone regarding market challenges.
AI-powered briefs, options data, and 20 quarters of history — everything you need before earnings.
No charge today · Auto-bills $8/mo after 7 days · Cancel anytime
MONOLITHIC PWR SYS I
Oct 31, 2016